黄芪甲苷对东莨菪碱致小鼠记忆障碍的保护作用及机制

摘要/Abstract

摘要： 目的

观察黄芪甲苷对东莨菪碱致小鼠学习记忆障碍的改善作用及其抗氧化机制。

方法

将小鼠随机分为空白对照组、模型组、阳性对照组、黄芪甲苷高、中、低浓度组，连续灌胃给药14天后，除空白组外，其余各组小鼠腹腔注射东莨菪碱制备记忆障碍模型。造模后，采用避暗实验观察记录步入潜伏期和错误频次，采用Morris 水迷宫实验观察记录各天逃避潜伏期、进入目标象限次数、目标象限内游泳时间、目标象限内游泳路程。行为学检测结束后检测各组小鼠脑组织中总超氧化物歧化酶（T-SOD）、丙二醛（MDA）的水平。

结果

与空白对照组小鼠相比，模型组小鼠步入潜伏期显著缩短（P< 0.05）、错误频次显著增加（P< 0.05），各天逃避潜伏期显著延长（P< 0.05），目标象限次数、在目标象限内游泳时间、在目标象限内游泳路程3个指标均显著降低（P< 0.05），脑组织MDA含量显著升高（P< 0.05），T-SOD活力显著降低（P< 0.05）。与模型组小鼠相比，黄芪甲苷高、中浓度组小鼠步入潜伏期显著延长（P< 0.05），黄芪甲苷高、中、低浓度组小鼠错误频次显著减少（P< 0.05），黄芪甲苷中浓度组小鼠各天逃避潜伏期显著缩短（P< 0.05）、进入目标象限的次数、在目标象限内的游泳时间、在目标象限内游泳路程显著增加（P< 0.05），黄芪甲苷高浓度组小鼠在目标象限内的游泳时间、在目标象限内游泳路程显著增加（P< 0.05），黄芪甲苷高、中、低浓度组小鼠脑组织MDA含量显著降低（P< 0.05）、T-SOD活力显著升高（P< 0.05）。

结论

黄芪甲苷可以改善东莨菪碱致小鼠的学习记忆障碍，其作用机制可能与增加SOD水平和降低MDA水平有关。

关键词:黄芪甲苷,东莨菪碱,记忆障碍

Abstract: Objective

To study the improvement effects and antioxidant mechanisms of astragaloside Ⅳ on learning and memory disorder in mice with scopolamine.

Methods

The mice were randomly divided into blank control group， model group， positive control group， and the groups with high， medium and low concentration of astragaloside Ⅳ. After 14 days of continuous gavage， except for the blank group，all the other groups of mice were injected with scopolamine to prepare memory disorder models. After modeling， the dark-avoidance experiment was used to observe and record enter latency and error frequency， and the Morris water labyrinth experiment was used to observe and record each day escape latency， number of times into the target quadrant， swimming time in the target quadrant， swimming distance in the target quadrant. After the behavioral test， the levels of total superoxide dismutase （T-SOD） and malondialdehyde （MDA） in the brain tissue of each group were detected.

Results

Compared with blank group， the enter latency was shortened significantly in the model group （P< 0.05）， error frequency was increased significantly in the model group （P< 0.05）， the escaping incubation period was significantly prolonged in the model group （P< 0.05）， the target quadrant number， swimming time in the target quadrant and swimming distance in the target quadrant were significantly reduced in the model group （P< 0.05）， the level of MDA in the brain tissue of mice was increased significantly in the model group （P< 0.05），the activity of T-SOD was decreased significantly in the model group（P< 0.05）. Compared with the model group， the enter latency of mice with high and medium concentrations of Astragaloside Ⅳ was significantly prolonged （P< 0.05）， the frequency of errors of mice with high， medium and low concentrations of astragaloside Ⅳ were significantly reduced （P< 0.05）， the escape latency of mice with medium concentrations of astragaloside Ⅳwas significantly shortened （P< 0.05）， the number of times of entering the target quadrant， the swimming time in the target quadrant， and the swimming distance in the target quadrant were increased significantly （P< 0.05）. The swimming time in the target quadrant and the swimming distance in the target quadrant of mice with high concentration of Astragaloside Ⅳ were significantly increased （P< 0.05）. The levels of malondialdehyde （MDA） in the brain tissue of mice with high， medium and low concentrations of astragaloside Ⅳ were significantly detected （P< 0.05）， and the activity of total superoxide dismutase （T-SOD） was significantly increased（P< 0.05）.

Conclusion

Astragaloside Ⅳcan improve learning and memory impairment induced by scopolamine in mice， the mechanism may be related to increasing SOD level and reducing MDA level.

Key words:astragaloside Ⅳ,scopolamine,learning and memory impairment

中图分类号:

R969.4

吴月鹏, 邱爽, 康妍, 高敏, 陈美华, 张颜波. 黄芪甲苷对东莨菪碱致小鼠记忆障碍的保护作用及机制[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(10): 734-738.

Yuepeng Wu, Shuang Qiu, Yan Kang, Min Gao, Meihua Chen, Yanbo Zhang. The protective effects and mechanisms of astragaloside Ⅳ on memory disorder in mice induced by scopolamine[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(10): 734-738.

图/表4

组别	剂量（mg/kg）	步入潜伏期（s）	错误频次（次）
高浓度	200	30.00 ± 12.67^*	4.75 ± 0.96^*
中浓度	100	29.00 ± 6.48^*	4.00 ± 0.81^*
低浓度	50	27.75 ± 7.58	4.50 ± 1.29^*
模型组		13.75 ± 8.95^#	6.75 ± 1.26^#
阳性对照组	30	41.50 ± 7.78^*	2.87 ± 0.63^*
空白对照组		41.66 ± 13.61^*	2.75 ± 0.96^*

组别	剂量（mg/kg）	步入潜伏期（s）	错误频次（次）
高浓度	200	30.00 ± 12.67^*	4.75 ± 0.96^*
中浓度	100	29.00 ± 6.48^*	4.00 ± 0.81^*
低浓度	50	27.75 ± 7.58	4.50 ± 1.29^*
模型组		13.75 ± 8.95^#	6.75 ± 1.26^#
阳性对照组	30	41.50 ± 7.78^*	2.87 ± 0.63^*
空白对照组		41.66 ± 13.61^*	2.75 ± 0.96^*

组别	剂量（mg/kg）	逃避潜伏期
高浓度	200	47.65 ± 6.99	44.49 ± 9.69	42.65 ± 4.55	41.50 ± 9.85	38.00 ± 3.54
中浓度	100	41.09 ± 7.68^*	40.01 ± 2.49^*	38.81 ± 8.33^*	35.46 ± 2.47^*	31.68 ± 6.27^*
低浓度	50	46.13 ± 4.52	44.26 ± 2.86	41.73 ± 3.57	39.18 ± 7.07	36.06 ± 4.92
模型组		53.81 ± 7.18^#	49.81 ± 4.31^#	47.63 ± 6.69^#	46.36 ± 9.67^#	43.89 ± 4.83^#
阳性对照组	30	42.33 ± 5.29^*	37.18 ± 4.82^*	36.48 ± 1.37^*	33.62 ± 5.28^*	29.93 ± 8.77^*
空白对照组		39.71 ± 3.93^*	36.43 ± 9.16^*	32.02 ± 1.90^*	30.75 ± 5.95^*	28.08 ± 4.18^*

组别	剂量（mg/kg）	逃避潜伏期
高浓度	200	47.65 ± 6.99	44.49 ± 9.69	42.65 ± 4.55	41.50 ± 9.85	38.00 ± 3.54
中浓度	100	41.09 ± 7.68^*	40.01 ± 2.49^*	38.81 ± 8.33^*	35.46 ± 2.47^*	31.68 ± 6.27^*
低浓度	50	46.13 ± 4.52	44.26 ± 2.86	41.73 ± 3.57	39.18 ± 7.07	36.06 ± 4.92
模型组		53.81 ± 7.18^#	49.81 ± 4.31^#	47.63 ± 6.69^#	46.36 ± 9.67^#	43.89 ± 4.83^#
阳性对照组	30	42.33 ± 5.29^*	37.18 ± 4.82^*	36.48 ± 1.37^*	33.62 ± 5.28^*	29.93 ± 8.77^*
空白对照组		39.71 ± 3.93^*	36.43 ± 9.16^*	32.02 ± 1.90^*	30.75 ± 5.95^*	28.08 ± 4.18^*

组别	剂量（mg/kg）		目标象限内
高浓度	200	5.25 ± 1.25	20.06 ± 0.95^*	617.54 ± 96.05^*
中浓度	100	6.50 ± 1.91^*	20.07 ± 2.00^*	586.1 ± 129.17^*
低浓度	50	4.25 ± 1.26	17.24 ± 0.35	454.54 ± 68.53
模型组		3.50 ± 1.29^#	16.47 ± 0.89^#	418.95 ± 118.7^#
阳性对照组	30	7.25 ± 0.96^*	22.92 ± 0.68^*	777.76 ± 89.95^*
空白对照组		8.00 ± 0.82^*	24.14 ± 3.41^*	941.2 ± 75.16^*

组别	剂量（mg/kg）		目标象限内
高浓度	200	5.25 ± 1.25	20.06 ± 0.95^*	617.54 ± 96.05^*
中浓度	100	6.50 ± 1.91^*	20.07 ± 2.00^*	586.1 ± 129.17^*
低浓度	50	4.25 ± 1.26	17.24 ± 0.35	454.54 ± 68.53
模型组		3.50 ± 1.29^#	16.47 ± 0.89^#	418.95 ± 118.7^#
阳性对照组	30	7.25 ± 0.96^*	22.92 ± 0.68^*	777.76 ± 89.95^*
空白对照组		8.00 ± 0.82^*	24.14 ± 3.41^*	941.2 ± 75.16^*

组别	剂量（mg/kg）	MDA（nmol/mgprot）	T-SOD（U/mgprot）
高浓度	200	8.78 ± 0.66^*	107.34 ± 3.40^*
中浓度	100	6.55 ± 0.36^*	111.87 ± 4.72^*
低浓度	50	8.66 ± 0.45^*	106.77 ± 4.69^*
模型组		11.45 ± 0.50^#	101.10 ± 6.31^#
阳性对照组	30	5.87 ± 0.38^*	114.29 ± 4.23^*
空白对照组		5.42 ± 0.35^*	118.40 ± 4.57^*

组别	剂量（mg/kg）	MDA（nmol/mgprot）	T-SOD（U/mgprot）
高浓度	200	8.78 ± 0.66^*	107.34 ± 3.40^*
中浓度	100	6.55 ± 0.36^*	111.87 ± 4.72^*
低浓度	50	8.66 ± 0.45^*	106.77 ± 4.69^*
模型组		11.45 ± 0.50^#	101.10 ± 6.31^#
阳性对照组	30	5.87 ± 0.38^*	114.29 ± 4.23^*
空白对照组		5.42 ± 0.35^*	118.40 ± 4.57^*

参考文献13

1	Eleonora N， Ryan H， Anthony F， et al. Alzheimer's disease： A tale of two diseases？［J］. Neural Regeneration Research， 2021， 16（10）： 1958.
2	Jellinger K. Prevalence of Alzheimer's disease in very elderly people： A prospective neuropathological study［J］. Neurology， 2002， 58（4）： 671.
3	Jiang LW， Qu M， Hassan SS， et al. Enhancing therapeutic efficacy of donepezil by combined therapy： A comprehensive review［J］.Current Pharmaceutical Design， 2021， 27（3）：332.
4	Jessen F， Block W， Traber F， et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD［J］. Neurology， 2000， 55（5）： 684.
5	靳晓飞，张彐宁，周晓红，等.黄芪甲苷调控自噬减轻氧糖剥夺/复氧复糖PC12细胞氧化应激损伤研究［J］.中国药理学通报， 2020， 36（1）：53.
7	Sangeeta P， Swapnil S， Sarvesh KP， et al. Role of Crataegusoxyacantha （Hawthorn） on scopolamine induced memory deficit and monoamine mediated behaviour in rats［J］. Advances in Traditional Medicine， 2017， 17（4）：315.
8	童庆，吴晓军，张盼红，等.建立小鼠学习记忆损伤模型的方法学研究［J］.实验动物科学， 2019， 36（2）：21.
9	Li AP， Zhao H， Li S， et al. Species differences of muridae in thelearning and memory behavior in morris water maze［J］. Chin JBehav Med Sci， 2005， 14（1）：29.
10	Association Alzheimer's. 2015 Alzheimer's disease facts andfigures［J］. Alzheimers Dement， 2015， 11（3）： 332.
11	Cervellatic C， Wood PL， Romani A， et al. Oxidative challenge in Alzheimer's disease：State of knowledge and future needs ［J］. Investig Med， 2016， 64（1）：21.
12	Yang WT， Zheng XW， Chen S， et al. Chinese herbal medicine for Alzheimer's disease： Clinical evidence and possible mechanism of neurogenesis［J］. Biochemical Pharmacology， 2017， 141：143.
13	Pan YF， Jia XT， Song EF， et al. Astragalo side Ⅳ protects against Aβ1-42-induced Oxidative stress， neuro inflammation and cognitive impairment in rats［J］. Chinese Medical Sciences Journal， 2018， 33（1）：29.